Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharmaceutical company Optimer Pharmaceuticals (NASDAQ: OPTR) shed as much as 16% after the company reported disappointing first-quarter results.
So what: For the quarter, Optimer delivered a 35% increase in revenue to $19.4 million as sales of its Clostridium difficile-associated diarrhea drug Dificid rose to $16.8 million from $14.4 million in the year-ago period. Net loss per share widened significantly to $0.65 from $0.23 per share in the previous year. Wall Street had been expecting Optimer to report a smaller loss of $0.46 per share on revenue of $21.3 million.
Now what: And investors are expecting a high premium for these results? Optimer has made no qualms about potentially putting itself up for sale, and rumors have been flying that it could command as much as $1 billion. However, following today's results, potential buyers are going to see that Dificid sales aren't growing nearly as fast as anyone expected and that Optimer is incredibly pricey relative to the peak sales potential of its lone FDA-approved drug. This remains a biopharmaceutical company I would highly suggest keeping your distance from.
Craving more input? Start by adding Optimer Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.
